1 feb 2021
Junshi Biosciences and Coherus BioSciences Announce Collaboration to Co-Develop Anti-PD-1 Antibody, Toripalimab, in U.S. and Canada
Junshi Biosciences to receive up to an aggregate of US$1.11 billion of upfront payment, exercise fee and milestone payments from Coherus for the grant of the license of toripalimab and the two option programs (if exercised) in US and Canada
The first toripalimab BLA to be filed with the US FDA for nasopharyngeal carcinoma later this year
SHANGHAI, China, Feb. 01, 2021 (GLOBE NEWSWIRE) Junshi Biosciences (HKEX: 1877; SSE: 688180), an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, today announced a collaboration with Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) for the development and commercialization of toripalimab, Junshi Biosciences’ anti-PD-1 antibody, in the United States and Canada.
Junshi Biosciences: New data show treatment with etesevimab (JS016) and bamlanivimab together reduced risk of COVID-19 hospitalizations and death by 70 percent
Results from more than 1,000 high-risk patients were consistent with previous data
In November, Lilly submitted a EUA request to the FDA for etesevimab and bamlanivimab together for mild to moderate COVID-19 in high-risk patients, which remains under review by the FDA
Findings from BLAZE-4 trial provide data on lower doses of etesevimab and bamlanivimab together
SHANGHAI, China, Jan. 26, 2021 (GLOBE NEWSWIRE) Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that etesevimab (JS016 or LY-CoV016) 2800 mg and bamlanivimab (LY-CoV555) 2800 mg together significantly reduced COVID-19-related hospitalizations and deaths (collectively, events ) in high-risk patients recently diagn
Trial met primary endpoint and key secondary endpoints with high statistical significance
Results from more than 1,000 high-risk patients were consistent with previous data
In November, Lilly submitted a EUA request to the FDA for etesevimab and bamlanivimab together for mild to moderate COVID-19 in high-risk patients, which remains under review by the FDA
Findings from BLAZE-4 trial provide data on lower doses of etesevimab and bamlanivimab together
SHANGHAI, China, Jan. 26, 2021 (GLOBE NEWSWIRE) Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that etesevimab (JS016 or LY-CoV016) 2800 mg and bamlanivimab (LY-CoV555) 2800 mg together significantly reduced COVID-19-related hospitalizations and deaths (collectively, “events”) in high-risk patients recently diagnosed with COVID-19, meeting the primary endpoint of the Phase 3 BL
FDA Grants Toripalimab Fast Track Designation for Mucosal Melanoma | Comunicados | Edición USA efe.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from efe.com Daily Mail and Mail on Sunday newspapers.